AuroSource joins India’s $1.5bn CRAMS sector

By Staff reporter

- Last updated on GMT

Related tags: Pharmacology

Indian generic drugmaker Aurobindo Pharma officially launched its CRAMS unit AuroSource last week, also unveiling plans for an R&D facility in Pashamylaram near Hyderabad, India.

The new division, which will provide medicinal chemistry and active pharmaceutical ingredient (API) development services at six facilities across India, is intended to capture a share of the country’s $1.5bn (€1.1bn) contract research and manufacturing services (CRAMS) sector.

AuroSource suggested that: “This is a critical time to enter the [CRAMS] market,” ​and added that Big Pharma’s adoption of outsourcing strategies as a key driver for development of the new business.

The firm also said that: “Impending reforms in the US healthcare market have exposed a need for contract manufacturing services.​”

Generics licensing deal

In other news, Aurobindo is set to sign several new generics licensing deals with several major global drugmakers according to Ramprasad Reddy, Chairman of Aurobindo.

He told expressbuzz​ that the firm, which recently signed a generics licensing agreement with US drug giant Pfizer, “anticipate to close deals with 2-3 multinationals over the next few months​.”

Aurobindo will also join the $8bn a year oral contraceptives sector in the next three years, initially targeting the US that, the firm said, accounts for some 45 per cent of the global market.

Reddy explained to the Financial Express​ that the company’s manufacturing plant for oral contraceptives is expected to be ready in the next five to six months.

We hope to launch the first generic oral contraceptive product during the first quarter of FY12 in the regulated markets,​’’ he added.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more